Results 31 to 40 of about 643,840 (294)

Placebo Economics: A Systematic Review About the Economic Potential of Utilizing the Placebo Effect

Frontiers in Psychiatry, 2019
Background: Recent research shows that placebo mechanisms can be utilized in ethical and legal ways such as in open-label conditions, when patients know that they receive placebos, and through psychological interventions aiming to optimize patients ...
Jens Hamberger, Jens Hamberger, Karin Meissner, Karin Meissner, Thilo Hinterberger, Thomas Loew, Katja Weimer   +6 more
doaj   +1 more source

Telomere length as a predictor of response to Pioglitazone in patients with unremitted depression: a preliminary study. [PDF]

, 2016
We studied peripheral leukocyte telomere length (LTL) as a predictor of antidepressant response to PPAR-γ agonist in patients with unremitted depression.
Blackburn, E, Epel, E, Lin, J, Lin, KW, Rasgon, N   +4 more
core   +1 more source

Secukinumab versus adalimumab for psoriatic arthritis: comparative effectiveness up to 48 weeks using a matching-adjusted indirect comparison [PDF]

, 2018
Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor ...
Gandhi, Kunal, Hunger, Matthias, Jugl, Steffen M., Karabis, Andreas, McInnes, Iain B., Mease, Philip J., Mpofu, Shephard, Nash, Peter, Thom, Howard   +8 more
core   +2 more sources

Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response. [PDF]

, 2017
BACKGROUND: Sunitinib prolongs progression-free survival (PFS) in patients with advanced pancreatic neuroendocrine tumours (pNET). Response Evaluation Criteria in Solid Tumors (RECIST)-defined partial responses (PR; classically defined as ⩾30% size ...
A Sundin, AA van der Veldt, Angela Lamarca, BE Houk, Catherine Lombard-Bohas, E Raymond, EA Eisenhauer, Eric Raymond, Heinz-Josef Lenz, HX Chen, HZ Shi, Ivan Borbath, James Posey, JC Yao, Jean Luc Raoul, Jorge Barriuso, Juan W Valle, KM Krajewski, KM Krajewski, Matthew Kulke, MC Ornstein, MH Kulke, Neal J Meropol, P Therasse, R Thiam, S Faivre, S Patel, Sandrine Faivre   +27 more
core   +2 more sources

The 24 hour lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease [PDF]

, 2014
Background: Olodaterol is a once-daily long-acting β2-agonist being investigated for the treatment of chronic obstructive pulmonary disease, with ≥ 24 hour bronchodilator activity.
Aumann, Joseph-Leon, Derom, Eric, Hamilton, Alan, Lange, Peter, Tetzlaff, Kay, Ting, Naitee   +5 more
core   +2 more sources

A double-blind study of the efficacy of apomorphine and its assessment in "off-periods in Parkinson's disease [PDF]

, 1993
Five patients with idiopathic Parkinson's disease with severe response fluctuations were selected for a randomized double-blind placebo-controlled study, concerning the clinical effects of subcutaneous apomorphine and its assessment in `off¿-periods. The
Essink, A.W.G., Jansen, E.N.H., Laar, T. van, Neef, C., Oosterloo, S.   +4 more
core   +3 more sources

Placebo response in migraine [PDF]

European Journal of Clinical Pharmacology, 2010
Sir I am currently in the process of revising the Guidelines for Drug Trials in Migraine of The International Headache Society. While browsing the literature for information on the placebo response in migraine randomised clinical trials (RCTs), I read with interest the extensive meta-analysis on this subject published by Macedo et al.
openaire   +3 more sources

Placebo and the law of identification

Frontiers in Psychiatry
Thousands of essays and studies have been published on placebo and nocebo. Yet, despite this plethora of information, we are not much closer to a comprehensive understanding of the fundamental mechanism producing placebo and nocebo effects than we were ...
Steve F. Bierman, Andrew Weil, Stephen Dahmer   +2 more
doaj   +1 more source

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3) [PDF]

, 2018
Background: The study aimed to assess 52-week efficacy and safety of secukinumab self-administration by autoinjector in patients with active psoriatic arthritis (PsA) in the FUTURE 3 study (ClinicalTrials.gov NCT01989468).
Andersson, Mats, Blanco, Ricardo, Dokoupilova, Eva, FUTURE 3 study group, Kajekar, Radhika, McInnes, Iain B, Mease, Philip J, Mpofu, Shephard, Nash, Peter, Pricop, Luminita, Rahman, Proton, Ritchlin, Christopher T   +11 more
core   +1 more source

Placebo response in depression

Dialogues in Clinical Neuroscience, 2002
With its naturally fluctuating course, depression is a highly placebo-responsive condition: mean placebo response rates in antidepressant clinical trials are 30% to 40%. We review the history and terminology of placebo and the proposed mechanisms underlying the placebo response, including the physician-patient relationship and biological, sociocultural,
Shamsah B, Sonawalla, Jerrold F, Rosenbaum   +1 more
openaire   +3 more sources